Abstract
The development of personalized medicine in oncology is based on biomarkers that help select populations for more efficient and less toxic therapies. The onset of molecular biology led to new paradigms in drug development, with efficacy data reported in early clinical trials and accelerated approvals. Multiple clinical trials, including SHIVA, SAFIR-01 and MOSCATO-01, have been developed to evaluate the interest of treatment decision-making based on tumor molecular profiling, with the ambition to replace historical clinical and pathological classifications. Targeted molecular therapies have also drastically enhanced the prognosis of patients in several cancer subtypes, with increased use in the context of advanced palliative care. Breaking through those boundaries might lead to a true precision medicine in oncology, which implementation in clinical routine is now expected by patients and physicians.
Translated title of the contribution | Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie |
---|---|
Original language | English |
Pages (from-to) | 735-743 |
Number of pages | 9 |
Journal | Bulletin du Cancer |
Volume | 104 |
Issue number | 9 |
DOIs | |
Publication status | Published - 1 Sept 2017 |
Keywords
- Biomarker
- Molecular targeted therapies
- Personalized medicine